New pill could make IVF easier and more effective
NCT ID NCT07236476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an oral drug called LY01021 in about 90 women undergoing IVF or ICSI. The drug aims to prevent premature hormone surges that can disrupt egg retrieval. Researchers are testing three doses to find the best balance of effectiveness and safety, with the goal of improving pregnancy rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY01021 (oral drug to control hormone levels during IVF)
What this could lead to
If successful, this could provide a more convenient oral option to prevent premature ovulation during IVF, potentially improving egg retrieval and pregnancy rates.
What could go wrong
This is an early phase 2 dose-finding study with only 90 participants. The drug may not work better than existing treatments, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASSISTED REPRODUCTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Third Hospital
Beijing, China